A*STAR's Singapore Immunology Network Is the First GeneGo Center of Excellence in Asia

Thursday, December 11, 2008 General News J E 4
ST. JOSEPH, Mich., Dec. 10 GeneGo, Inc., a leadingprovider of software and databases for systems biology and pathway analysis,today announced that A*STAR's Singapore Immunology Network (SIgN) has become acertified GeneGo Center of Excellence (COE). SIgN researchers will have accessto GeneGo's MetaCore, training and advanced support. SIgN COE will provide apathway analysis environment for all SIgN researchers.

"We are excited to work with SIgN, one of the premium life sciencesresearch institutes in the world," said Julie Bryant, Vice President ofBusiness Development at GeneGo. "We look forward to building closerrelationships with SIgN investigators and growing the number of MetaCore usersin Singapore."

About GeneGo, Inc.

GeneGo, Inc. develops systems biology technology such as compound basedpathway analysis, cheminformatics & bioinformatics software for life scienceresearch. The original computational MetaDiscovery(TM) platform allows anintegration and expert analysis of different kinds of experimental data (mRNAexpression, proteomics, metabolomics, microRNA assays and other phenotypicdata) and relevant bioactive chemistry (metabolites, drugs, other xenobiotics)within the framework of curated biological pathways and networks. GeneGo'sflagship product, MetaCore 5.1(TM), assists pharmaceutical scientists in theareas of target selection and validation, data mining in biology,identification of biomarkers for disease states and toxicology. The secondproduct, MetaDrug 5.1(TM) is designed for prediction of human metabolism,toxicity and biological effects for novel small molecules compounds.MetaBase(TM) represents the knowledge base for MetaCore.

For more information, please visit the company's web site at

SOURCE GeneGo, Inc.


You May Also Like

View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
Valeant to Acquire Dow Pharmaceutical Sciences, In...
Halozyme Therapeutics Begins Phase 1 Clinical Tria...